% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Obermller:302847,
      author       = {D. Obermüller and K. Berger$^*$ and R. Klamroth and M.
                      Kleppisch and S. Rauchensteiner and I. Ecke and S. Hermann
                      and D. Pawlowska-Phelan and D. Häckl and A. Kisser},
      title        = {{E}pidemiology, {H}ealth {C}are {R}esource {U}tilization,
                      and {C}osts of {H}emophilia {A} and {B} by {T}reatment
                      {R}egimen: {A} {R}etrospective {A}nalysis of {G}erman
                      {C}laims {D}ata from 2016 to 2021.},
      journal      = {Hämostaseologie},
      volume       = {nn},
      issn         = {0720-9355},
      address      = {Stuttgart},
      publisher    = {Thieme},
      reportid     = {DKFZ-2025-01387},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {In Germany, hemophilia patients with a severe bleeding
                      phenotype receive lifelong prophylactic treatment with
                      intravenous concentrated factor VIII (FVIII) or IX (FIX) to
                      prevent bleeding events. To assess the economic value of
                      emerging treatment options, studies describing the economic
                      burden of hemophilia under the current standard of care in
                      Germany are needed.This study classified hemophilia A (HA)
                      and B (HB) patients by treatment regimen in administrative
                      claims data to examine the real-world economic burden of
                      Hemophilia in Germany from 2016 to 2021.Hemophilia patients
                      were identified in InGef statutory health insurance claims
                      data via ICD-10 codes D66 (HA) and D67 (HB) in combination
                      with one or more claims for hemophilia-related
                      medication.Each patient's factor regimen was classified as
                      either indicative of a severe phenotype needing prophylaxis
                      or a non-severe phenotype treated on demand using a
                      classification threshold of 100,000 International Units (IU)
                      FVIII/year (HA) and 80,000 IU FIX/year (HB). Health care
                      resource utilization and cost outcomes were captured for
                      each study year.Male prevalence per 100,000 ranged from 6.39
                      to 7.81 (HA) and 1.26 to 1.89 (HB), with 43 to $53\%$ (HA)
                      and 40 to $56\%$ (HB) categorized as severe. In 2021, mean
                      (standard deviation [SD]) per-patient medication costs were
                      €321,987 (€157,915) in the severe treatment group versus
                      €43,487 (€92,821) in the non-severe group for HA and
                      €289,411 (€132,400) versus €19,253 (€23,655) for
                      HB.The results demonstrate the high economic burden of
                      severe HA and HB in Germany, driven by the need for
                      continuous factor replacement therapy, and give an estimate
                      of treatment costs based on a real-world therapy mix.},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40659341},
      doi          = {10.1055/a-2558-9886},
      url          = {https://inrepo02.dkfz.de/record/302847},
}